Uterine and Ovary Carcinosarcomas

Abstract

Uterine and ovary carcinosarcomas present a worse prognosis. On the basis of the present study data, although it should be prospectively confirmed, a sequential or multimodal adjuvant therapy should be proposed to patients with early-stage uterine and ovary carcinosarcomas.

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study

“…Ovarian carcinosarcoma (OCS) is a very rare ovarian tumor that accounts for only 1% of ovarian cancer, and is composed of both malignant epithelial and mesenchymal elements, as well as UCS [12]. Prognosis of UCS and OCS is poor because up to 2/3 of patients present with advanced stage [23].…”

“…Ovarian carcinosarcoma (OCS) is a very rare ovarian tumor that accounts for only 1% of ovarian cancer, and is composed of both malignant epithelial and mesenchymal elements, as well as UCS [12]. Prognosis of UCS and OCS is poor because up to 2/3 of patients present with advanced stage [23]. Currently, prognostic factors of carcinosarcoma (CS) are not well defined, but published reports have suggested pathological features and age as prognostic factors [456].…”

Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature

“…Ovarian carcinosarcomas, also known as malignant mixed Mullerian tumors (MMMT), represent 1% of all histologic subtypes of ovarian cancers and remain poorly understood [ 1 ]. While ovarian carcinosarcomas were once thought to be “collision tumors” with the presence of synchronous epithelial carcinoma and stromal sarcoma components, current data suggest they are de-differentiated carcinomas with cells that have a sarcomatous appearance and also cells with a carcinomatous histology [ 2 ].…”

“…While ovarian carcinosarcomas were once thought to be “collision tumors” with the presence of synchronous epithelial carcinoma and stromal sarcoma components, current data suggest they are de-differentiated carcinomas with cells that have a sarcomatous appearance and also cells with a carcinomatous histology [ 2 ]. Importantly, carcinosarcomas have been shown in multiple studies to be aggressive tumors, with one-third of patients having advanced disease at the time of diagnosis and a 60% overall recurrence rate [ 1 , 3 ]. A review of the Surveillance, Epidemiology, and End Results (SEER) Program data from 1998 to 2009 demonstrated that patients with ovarian carcinosarcoma have consistently poorer prognosis than those with high-grade papillary serous carcinoma of the ovary.…”

The Use of Lattice Radiation Therapy (LRT) in the Treatment of Bulky Tumors: A Case Report of a Large Metastatic Mixed Mullerian Ovarian Tumor

“…Most of them present as advanced disease and the median overall survival ranges from 7 to 27 months. The strongest prognostic factor is determined by FIGO staging [ 4 ]. Some reports indicate that complete cytoreduction, advanced age, grade of the sarcomatous component, and the use of adjuvant chemotherapy are the most important prognostic factors [ 4 - 5 ].…”